Plancorp LLC Invests $260,000 in Axon Enterprise, Inc $AXON

Plancorp LLC purchased a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 314 shares of the biotechnology company’s stock, valued at approximately $260,000.

Several other institutional investors and hedge funds also recently made changes to their positions in AXON. LaSalle St. Investment Advisors LLC lifted its position in Axon Enterprise by 2.1% in the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 16 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Axon Enterprise by 5.0% in the first quarter. Smartleaf Asset Management LLC now owns 379 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 18 shares during the last quarter. Pinion Investment Advisors LLC raised its stake in shares of Axon Enterprise by 3.0% in the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 19 shares during the last quarter. Kentucky Retirement Systems lifted its holdings in shares of Axon Enterprise by 0.4% during the first quarter. Kentucky Retirement Systems now owns 4,953 shares of the biotechnology company’s stock valued at $2,605,000 after purchasing an additional 19 shares in the last quarter. Finally, WCM Investment Management LLC boosted its position in shares of Axon Enterprise by 0.8% during the first quarter. WCM Investment Management LLC now owns 2,441 shares of the biotechnology company’s stock valued at $1,306,000 after buying an additional 19 shares during the last quarter. Institutional investors own 79.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. UBS Group reissued a “neutral” rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Morgan Stanley set a $885.00 price target on shares of Axon Enterprise and gave the stock an “overweight” rating in a research note on Friday, July 11th. Needham & Company LLC restated a “buy” rating and set a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. Finally, Wolfe Research started coverage on shares of Axon Enterprise in a research note on Monday, July 7th. They set an “outperform” rating for the company. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Insider Buying and Selling

In other news, President Joshua Isner sold 15,919 shares of the firm’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the transaction, the president owned 238,379 shares of the company’s stock, valued at $177,892,712.54. This trade represents a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hadi Partovi acquired 1,358 shares of the stock in a transaction dated Wednesday, August 13th. The shares were bought at an average cost of $740.00 per share, for a total transaction of $1,004,920.00. Following the completion of the transaction, the director owned 237,938 shares in the company, valued at approximately $176,074,120. This represents a 0.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 44,932 shares of company stock worth $34,408,816 in the last quarter. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Stock Performance

AXON opened at $712.15 on Friday. The company’s 50 day moving average is $759.55 and its 200 day moving average is $700.33. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. The company has a market cap of $55.90 billion, a price-to-earnings ratio of 175.84, a PEG ratio of 25.62 and a beta of 1.40. Axon Enterprise, Inc has a 12-month low of $388.37 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million for the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company’s quarterly revenue was up 32.6% on a year-over-year basis. During the same period last year, the firm earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.